1069-P: Safety and Efficacy of a Novel Basal-Bolus Insulin Delivery Device (IDD) in Adults with T2D Using Rapid-Acting or Regular Human Insulin

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1069-P
Author(s):  
RONNIE ARONSON ◽  
EDWARD T. MAHONEY ◽  
DRILON SALIU ◽  
LEYA BERGQUIST ◽  
LAURENCE HIRSCH
Keyword(s):  
Human Insulin ◽  
Insulin Delivery ◽  
Regular Human Insulin ◽  
Delivery Device ◽  
Safety And Efficacy ◽  
Bolus Insulin ◽  
Basal Bolus

PaQ®, a simple 3-day basal/bolus insulin delivery device, in people with type 2 diabetes

2013 ◽  
Author(s):  
J. K. Mader ◽  
L. C. Lilly ◽  
F. Aberer ◽  
J. Pachatz ◽  
S. Korsatko ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Delivery ◽  
Delivery Device ◽  
Bolus Insulin ◽  
Basal Bolus

scholarly journals A Feasibility Study of a 3-Day Basal-Bolus Insulin Delivery Device in Individuals With Type 2 Diabetes

Diabetes Care ◽  
2014 ◽  
Vol 37 (5) ◽  
pp. 1476-1479 ◽  
Author(s):  
Julia K. Mader ◽  
Leslie C. Lilly ◽  
Felix Aberer ◽  
Stefan Korsatko ◽  
Ellie Strock ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Feasibility Study ◽  
Insulin Delivery ◽  
Delivery Device ◽  
Bolus Insulin ◽  
Basal Bolus

scholarly journals Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen

Diabetologia ◽  
1995 ◽  
Vol 38 (5) ◽  
pp. 592-598 ◽  
Author(s):  
F. S. Nielsen ◽  
L. N. J�rgensen ◽  
M. Ipsen ◽  
A. I. Voldsgaard ◽  
H. -H. Parving
Keyword(s):  
Human Insulin ◽  
Insulin Analogue ◽  
Insulin Regimen ◽  
Bolus Insulin ◽  
Basal Bolus

Clinical experiences with basal analogue insulin in routine care. Retrospective follow up analysis of a database from daily routine care

2013 ◽  
Vol 154 (37) ◽  
pp. 1476-1484
Author(s):  
Zsolt Sudár ◽  
Lajos Muth ◽  
Csaba Nyirati ◽  
Vince Szí ◽  
János Tornóczky ◽  
...  
Keyword(s):  
Body Weight ◽  
Metabolic Control ◽  
Human Insulin ◽  
Insulin Dose ◽  
Routine Care ◽  
Analogue Insulin ◽  
Bolus Insulin ◽  
Basal Bolus

Introduction: Basal-bolus insulin regime is frequently used in type 2 diabetes in order to improve metabolic control and decrease the risk of complications. A general question is, however, the effect of application of analogue insulin in comparison to human insulin regimes. Aim: The aim of the authors was to perform a retrospective database analysis among patients who were switched from human insulin only based basal-bolus regime to analogue only insulin regime in order to examine changes in metabolic control, body weight, insulin dose and basal:bolus insulin ratio. Method: Type 2 diabetic patients (n = 137) were enrolled who used once daily basal insulin with complementary bolus insulin given at main meals, and human insulin was switched to analogue insulin. Patients were divided into two groups using detemir (n = 103) or glargine (n = 34). Results: During 17 months ofanalogue insulin treatment the HbA1c was decreased by 0.34% (detemir –0.44%; glargine –0.17%). Body weight was increased by 1.11 kg (detemir +1.0 kg; glargine +1.43 kg). The basal:bolus insulin ratio increased in all groups (entire cohort 6.04%, detemir 5.26%, glargine 8.37%). The average insulin dose was 80.76 units at the end of follow up. There was no significant difference in terms of total and basal insulin doses between detemir (27.89 and 79.78 U, respectively) and glargine group (32.85 and 83.74 U, respectively). Conclusions: These results support that switching from human to analogue insulin in basal-bolus regime could improve the metabolic control by increasing dose of basal analogue insulin and basal: bolus ratio. Both detemir and glargine can provide similar improvement in metabolic control with the same insulin dose but with relatively more weight gain with glargine. Orv. Hetil., 2013, 154, 1476–1484.

Sign in / Sign up

Export Citation Format

Share Document